Isotechnika Inc. announced that the Company has enrolled its first patient in a pivotal Phase III European/Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247.
Vanda Pharmaceuticals Inc. announced positive top-line results from the company's Phase III clinical trial evaluating iloperidone, an atypical antipsychotic, in patients with schizophrenia.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment